[go: up one dir, main page]

EA201700123A1 - Способ прогнозирования варианта лекарственного препарата для лечения депрессии - Google Patents

Способ прогнозирования варианта лекарственного препарата для лечения депрессии

Info

Publication number
EA201700123A1
EA201700123A1 EA201700123A EA201700123A EA201700123A1 EA 201700123 A1 EA201700123 A1 EA 201700123A1 EA 201700123 A EA201700123 A EA 201700123A EA 201700123 A EA201700123 A EA 201700123A EA 201700123 A1 EA201700123 A1 EA 201700123A1
Authority
EA
Eurasian Patent Office
Prior art keywords
depression
pea
patient
treatment
predicting
Prior art date
Application number
EA201700123A
Other languages
English (en)
Other versions
EA034419B1 (ru
Inventor
Нориюки Кавамура
Хаджиме Сато
Куми Ямаки
Тамаки Фуджимори
Хироюки Ямамото
Ёшиаки Онаши
Original Assignee
Хьюман Метаболоми Текнолоджис Инк.
Гёкикай Медикал Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хьюман Метаболоми Текнолоджис Инк., Гёкикай Медикал Корпорейшн filed Critical Хьюман Метаболоми Текнолоджис Инк.
Publication of EA201700123A1 publication Critical patent/EA201700123A1/ru
Publication of EA034419B1 publication Critical patent/EA034419B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Задача: обеспечить способ, в котором фосфоэтаноламин (ФЭА), выступающий в качестве биомаркёра депрессии, непосредственно связан с лечением. Решение: способ прогнозирования вариантов лекарственных препаратов для лечения депрессии включает следующие шаги: (1) измерение уровня ФЭА в крови, взятой у пациента с подозрением на депрессию; (2) определение того, является ли уровень ФЭА в крови пациента ниже, чем эталонное значение, отличающееся тем, что если измеренное значение пациента ниже значений, полученных у здоровых людей, пациент страдает депрессией, характеризуемой пониженным уровнем ФЭА, выступающим в качестве индикатора; и (3) прогнозирование вариантов лекарственных препаратов для лечения депрессии на основании наличия или отсутствия пониженного уровня ФЭА в крови пациента.
EA201700123A 2014-09-26 2015-09-24 Способ выбора лекарственного препарата для лечения депрессии EA034419B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014196043 2014-09-26
PCT/JP2015/076903 WO2016047677A1 (ja) 2014-09-26 2015-09-24 うつ病治療薬の選択肢を予測する方法

Publications (2)

Publication Number Publication Date
EA201700123A1 true EA201700123A1 (ru) 2017-09-29
EA034419B1 EA034419B1 (ru) 2020-02-06

Family

ID=55581200

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700123A EA034419B1 (ru) 2014-09-26 2015-09-24 Способ выбора лекарственного препарата для лечения депрессии

Country Status (7)

Country Link
US (1) US20170176412A1 (ru)
EP (1) EP3190413B1 (ru)
JP (1) JP6709887B2 (ru)
KR (1) KR102118780B1 (ru)
CN (1) CN106716129B (ru)
EA (1) EA034419B1 (ru)
WO (1) WO2016047677A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018062204A1 (ja) * 2016-09-30 2018-04-05 ヒューマン・メタボローム・テクノロジーズ株式会社 エタノールアミンリン酸の測定方法
WO2018061194A1 (ja) * 2016-09-30 2018-04-05 ヒューマン・メタボローム・テクノロジーズ株式会社 エタノールアミンリン酸の測定方法
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
KR20200049606A (ko) 2018-10-29 2020-05-08 고려대학교 산학협력단 항우울제 추천 방법 및 시스템
KR102120113B1 (ko) 2019-10-31 2020-06-17 모성희 티엠에스(tms)를 이용한 우울증치료 장치
GB201916185D0 (en) * 2019-11-07 2019-12-25 Randox Laboratories Ltd Biomarker of drug-induced cellular toxicity and depression
JP7544346B2 (ja) 2021-02-05 2024-09-03 医療法人社団行基会 精神疾患の検出方法
CN113117101A (zh) * 2021-05-28 2021-07-16 南昌大学 一种对抑郁症治疗药物的选项进行预测的方法
CN116500280B (zh) * 2023-06-26 2023-09-12 中国医学科学院北京协和医院 一组诊断颈动脉体瘤的标志物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536946A (ja) * 2005-04-22 2008-09-11 ワイス うつ病の処置または予防のための新規の治療的組み合わせ
JP2009007278A (ja) * 2007-06-27 2009-01-15 Argenes Inc 線維筋痛症の治療薬
NZ628281A (en) * 2008-12-09 2016-05-27 Stephanie Fryar Williams Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
US8951739B2 (en) * 2009-08-12 2015-02-10 Human Metabolome Technologies Inc. Biomarker for depression, method for measuring a biomarker for depression, computer program, and recording medium
DK2778233T3 (en) 2011-11-10 2017-03-20 Human Metabolome Tech Inc METHOD OF MEASURING ETHANOLAMINPHOSPHATE
JP6291158B2 (ja) * 2012-11-21 2018-03-14 サントリーホールディングス株式会社 抗認知症および学習記憶改善剤

Also Published As

Publication number Publication date
EP3190413A1 (en) 2017-07-12
CN106716129A (zh) 2017-05-24
EP3190413A4 (en) 2018-03-28
KR102118780B1 (ko) 2020-06-03
WO2016047677A1 (ja) 2016-03-31
CN106716129B (zh) 2019-04-19
JP6709887B2 (ja) 2020-06-17
EA034419B1 (ru) 2020-02-06
JPWO2016047677A1 (ja) 2017-07-06
US20170176412A1 (en) 2017-06-22
KR20170062478A (ko) 2017-06-07
EP3190413B1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
EA201700123A1 (ru) Способ прогнозирования варианта лекарственного препарата для лечения депрессии
ZA201803207B (en) MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
BR112016028958A2 (pt) método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento
PH12017501841A1 (en) Method for discriminating symptom of hepatic disease
MX2016006252A (es) Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono.
BR112015011359A2 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
BR112018003528A2 (pt) dispositivo para medição não invasiva de níveis de açúcar no sangue
MX387627B (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
EA201690537A1 (ru) Способы и средства для введения контрастной среды
MX2017010516A (es) Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea.
EA201891693A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови
GB2569932A (en) Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
EA201800413A1 (ru) Способ автоматического измерения вязкости крови
EA201001297A1 (ru) Способ диагностики меланомы человека на основании определения уровня экспрессии гена phf10, диагностический набор
RU2011116505A (ru) Способ диагностики различных форм острого пиелонефрита
UA91642U (ru) Способ определения степени токсемии у пациентов при микросатурнизме
EA201600668A3 (ru) Способ мониторинга эффективности противоопухолевой терапии немелкоклеточного рака легкого
MX357018B (es) Método de diagnóstico temprano de carcinoma hepatocelular.
RU2012129472A (ru) Способ определения прогрессии рака органов брюшной полости
Musialowska et al. ENDOCAN CONCENTRATION IN HYPERTENSIVE PATIENTS
RU2014154450A (ru) Способ диагностики псориаза
UA99717U (uk) Спосіб прогнозування досягнення цільового артеріального тиску у хворих з артеріальною гіпертензією та цукровим діабетом
UA96385U (uk) Спосіб визначення донороздатності населення

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM